Cargando…
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy
Acquired resistance to chemotherapy is an important clinical problem and can also occur without detectable cytogenetic aberrations or gene mutations. Chronic lymphocytic leukemia (CLL) is molecularly well characterized and has been elemental for establishing central paradigms in oncology. This promp...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195470/ https://www.ncbi.nlm.nih.gov/pubmed/32358561 http://dx.doi.org/10.1038/s41597-020-0456-0 |
_version_ | 1783528541529309184 |
---|---|
author | Yosifov, Deyan Yordanov Bloehdorn, Johannes Döhner, Hartmut Lichter, Peter Stilgenbauer, Stephan Mertens, Daniel |
author_facet | Yosifov, Deyan Yordanov Bloehdorn, Johannes Döhner, Hartmut Lichter, Peter Stilgenbauer, Stephan Mertens, Daniel |
author_sort | Yosifov, Deyan Yordanov |
collection | PubMed |
description | Acquired resistance to chemotherapy is an important clinical problem and can also occur without detectable cytogenetic aberrations or gene mutations. Chronic lymphocytic leukemia (CLL) is molecularly well characterized and has been elemental for establishing central paradigms in oncology. This prompted us to check whether specific epigenetic changes at the level of DNA methylation might underlie development of treatment resistance. We used Illumina Infinium HumanMethylation450 BeadChips to obtain DNA methylation profiles of 71 CLL patients with differential responses. Thirty-six patients were categorized as relapsed/refractory after treatment with fludarabine or bendamustine and 21 of them had genetic aberrations of TP53. The other 35 patients were untreated at the time of sampling and 15 of them had genetic aberration of TP53. Although we could not correlate chemoresistance with epigenetic changes, the patients were comprehensively characterized regarding relevant prognostic and molecular markers (e.g. IGHV mutation status, chromosome aberrations, TP53 mutation status, clinical parameters), which makes our dataset a unique and valuable resource that can be used by researchers to test alternative hypotheses. |
format | Online Article Text |
id | pubmed-7195470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-71954702020-05-06 DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy Yosifov, Deyan Yordanov Bloehdorn, Johannes Döhner, Hartmut Lichter, Peter Stilgenbauer, Stephan Mertens, Daniel Sci Data Data Descriptor Acquired resistance to chemotherapy is an important clinical problem and can also occur without detectable cytogenetic aberrations or gene mutations. Chronic lymphocytic leukemia (CLL) is molecularly well characterized and has been elemental for establishing central paradigms in oncology. This prompted us to check whether specific epigenetic changes at the level of DNA methylation might underlie development of treatment resistance. We used Illumina Infinium HumanMethylation450 BeadChips to obtain DNA methylation profiles of 71 CLL patients with differential responses. Thirty-six patients were categorized as relapsed/refractory after treatment with fludarabine or bendamustine and 21 of them had genetic aberrations of TP53. The other 35 patients were untreated at the time of sampling and 15 of them had genetic aberration of TP53. Although we could not correlate chemoresistance with epigenetic changes, the patients were comprehensively characterized regarding relevant prognostic and molecular markers (e.g. IGHV mutation status, chromosome aberrations, TP53 mutation status, clinical parameters), which makes our dataset a unique and valuable resource that can be used by researchers to test alternative hypotheses. Nature Publishing Group UK 2020-05-01 /pmc/articles/PMC7195470/ /pubmed/32358561 http://dx.doi.org/10.1038/s41597-020-0456-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the metadata files associated with this article. |
spellingShingle | Data Descriptor Yosifov, Deyan Yordanov Bloehdorn, Johannes Döhner, Hartmut Lichter, Peter Stilgenbauer, Stephan Mertens, Daniel DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy |
title | DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy |
title_full | DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy |
title_fullStr | DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy |
title_full_unstemmed | DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy |
title_short | DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy |
title_sort | dna methylation of chronic lymphocytic leukemia with differential response to chemotherapy |
topic | Data Descriptor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195470/ https://www.ncbi.nlm.nih.gov/pubmed/32358561 http://dx.doi.org/10.1038/s41597-020-0456-0 |
work_keys_str_mv | AT yosifovdeyanyordanov dnamethylationofchroniclymphocyticleukemiawithdifferentialresponsetochemotherapy AT bloehdornjohannes dnamethylationofchroniclymphocyticleukemiawithdifferentialresponsetochemotherapy AT dohnerhartmut dnamethylationofchroniclymphocyticleukemiawithdifferentialresponsetochemotherapy AT lichterpeter dnamethylationofchroniclymphocyticleukemiawithdifferentialresponsetochemotherapy AT stilgenbauerstephan dnamethylationofchroniclymphocyticleukemiawithdifferentialresponsetochemotherapy AT mertensdaniel dnamethylationofchroniclymphocyticleukemiawithdifferentialresponsetochemotherapy |